Alps Advisors Inc Nu Cana PLC Transaction History

Alps Advisors Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$2.7 - $5.04 $249,957 - $466,588	-92,577 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$4.38 - $7.0 $152,761 - $244,139	34,877 Added 60.45%	92,577 $462,000
Q4 2020 Feb 03, 2021	BUY	$4.4 - $5.59 $253,880 - $322,543	57,700 New	57,700 $259,000
Q3 2019 Nov 04, 2019	SELL	$6.95 - $10.71 $216,131 - $333,059	-31,098 Closed	0 $0
Q2 2019 Aug 07, 2019	SELL	$9.74 - $17.45 $455,247 - $815,613	-46,740 Reduced 60.05%	31,098 $323,000
Q1 2019 May 01, 2019	BUY	$10.92 - $18.03 $45,427 - $75,004	4,160 Added 5.65%	77,838 $1.32 Million
Q4 2018 Feb 04, 2019	BUY	$13.0 - $22.57 $224,367 - $389,535	17,259 Added 30.59%	73,678 $1.07 Million
Q3 2018 Oct 25, 2018	BUY	$20.12 - $26.86 $204,218 - $272,629	10,150 Added 21.94%	56,419 $1.41 Million
Q2 2018 Aug 02, 2018	BUY	$19.0 - $29.84 $207,860 - $326,449	10,940 Added 30.97%	46,269 $879,000
Q2 2018 Jul 25, 2018	SELL	$19.0 - $29.84 $141,208 - $221,770	-7,432 Reduced 17.38%	35,329 $357,000
Q1 2018 May 01, 2018	BUY	$10.04 - $28.25 $74,617 - $209,954	7,432 Added 21.04%	42,761 $809,000
Q4 2017 Feb 05, 2018	BUY	$10.0 - $18.72 $353,290 - $661,358	35,329	35,329 $357,000

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $59.5M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.